Roivant Sciences Ltd.

Listed Company

ROIVCIK 0001635088NasdaqLarge AcceleratedPharmaceutical PreparationsD0FY ends Mar 31

Period

FY 2026

Revenue

$8.26M

Net Income

$-299.77M

Total Assets

$5.71B

Equity

$4.53B

Shares Out

719.27M

Op. Cash Flow

$-750.35M

Business

Roivant Sciences Ltd. is a biopharmaceutical company that develops and commercializes therapeutic medicines and incubates discovery-stage and health technology companies. Its main products and candidates include small molecules (brepocitinib), biologics (IMVT-1402, batoclimab) and an inhaled sGC activator (mosliciguat), along with nucleic acid delivery technologies via Genevant. Roivant advances programs through subsidiary “Vants” such as Priovant, Immunovant, Pulmovant and Genevant, each focused on specific modalities and indications. Roivant operates globally through in‑licensing, collaborations, partnerships and clinical trials across the U.S., E.U. and other international markets.

Summary from filing dated 2025-05-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
Revenue	8	29	33
Operating expenses:	—	—	—
Cost of revenues	1	911,000	2
Research and development (includes $47,867, $39,780 and $32,400 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively)	682	550	440
Acquired in-process research and development	0	0	26
General and administrative (includes $298,297, $239,505, and $154,873 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively)	610	591	416
Total operating expenses	1,294	1,143	884
Gain on sale of Telavant net assets	0	110	5,348
Gain on litigation settlement	770	0	0
(Loss) income from operations	−515	−1,003	4,497
Change in fair value of investments	105	55	−48
Change in fair value of liability instruments	−48	16	−47
Gain on deconsolidation of subsidiaries	11	3	33
Interest income	178	258	146
Other (income) expense, net	4	−11	−14
(Loss) income from continuing operations before income taxes	−265	−682	4,568
Income tax expense	133	48	22
(Loss) income from continuing operations, net of tax	−398	−730	4,546
Income (loss) from discontinued operations, net of tax	0	373	−315
Net (loss) income	−398	−357	4,231
Net loss attributable to noncontrolling interests	−98	−185	−118
Net (loss) income attributable to Roivant Sciences Ltd.	−300	−172	4,349
Amounts attributable to Roivant Sciences Ltd.:	—	—	—
(Loss) income from continuing operations, net of tax	−300	−545	4,663
Income (loss) from discontinued operations, net of tax	0	373	−314
Net (loss) income attributable to Roivant Sciences Ltd.	−300	−172	4,349
Net (loss) income per common share, basic:	—	—	—
(Loss) income from continuing operations, net of tax (in dollars per share)	−0.43	−0.75	5.95
Income (loss) from discontinued operations, net of tax (in dollars per share)	0	0.51	−0.4
Net (loss) income (in dollars per share)	−0.43	−0.24	5.55
Net (loss) income per common share, diluted:	—	—	—
(Loss) income from continuing operations, net of tax (in dollars per share)	−0.54	−0.75	5.61
Income (loss) from discontinued operations, net of tax (in dollars per share)	0	0.51	−0.38
Net (loss) income (in dollars per share)	−0.54	−0.24	5.23
Weighted average shares outstanding:	—	—	—
Basic (in shares)	694	725	783
Diluted (in shares)	694	725	831

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31
Assets	—	—
Current assets:	—	—
Cash and cash equivalents	1,419	2,715
Marketable securities (held at fair value as of March 31, 2026)	2,873	2,171
Litigation settlement receivable	770	0
Other current assets	105	113
Total current assets	5,167	5,000
Property and equipment, net	12	12
Operating lease right-of-use assets	80	89
Investments measured at fair value	408	303
Other assets	41	33
Total assets	5,709	5,437
Liabilities and Shareholders’ Equity	—	—
Current liabilities:	—	—
Accounts payable	18	24
Accrued expenses	206	114
Operating lease liabilities	11	10
Income tax payable	46	416,000
Other current liabilities	583,000	1
Total current liabilities	281	149
Liability instruments measured at fair value	0	10
Operating lease liabilities, noncurrent	96	90
Income tax payable, noncurrent	39	0
Other liabilities	70,000	22,000
Total liabilities	416	250
Commitments and contingencies (Note 12)	—	—
Shareholders’ equity:	—	—
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 720,352,386 and 695,938,323 shares issued and outstanding at March 31, 2026 and 2025, respectively	0	0
Additional paid-in capital	5,025	4,562
(Accumulated deficit) / retained earnings	−502	116
Accumulated other comprehensive income	4	9
Shareholders’ equity attributable to Roivant Sciences Ltd.	4,527	4,688
Noncontrolling interests	765	500
Total shareholders’ equity	5,292	5,187
Total liabilities and shareholders’ equity	5,709	5,437

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
Cash flows from operating activities:	—	—	—
Net (loss) income	−398	−357	4,231
Adjustments to reconcile net (loss) income to net cash used in operating activities:	—	—	—
Share-based compensation	346	289	200
Change in fair value of investments	105	55	−48
Change in fair value of debt and liability instruments	−48	113	−79
Gain on sale of subsidiary interests	0	377	0
Gain on deconsolidation of subsidiaries	11	3	33
Gain on sale of Telavant net assets	0	110	5,348
Impairment loss on operating lease right-of-use assets	16	0	0
Accretion of discount and amortization of premium on available-for-sale marketable securities, net	23	0	0
Accretion of discount and amortization of premium on held-to-maturity marketable securities, net	14	70	0
Realized gain from sales of marketable securities	976,000	0	0
Loss on extinguishment of debt	0	−9	0
Depreciation and amortization	3	14	22
Non-cash lease expense	8	7	7
Other	−2	−4	−10
Changes in assets and liabilities, net of effects from acquisition and divestiture:	—	—	—
Other current assets	−11	25	81
Other assets	7	9	−16
Litigation settlement receivable	770	0	0
Accounts payable	3	−18	23
Accrued expenses	59	−10	40
Operating lease liabilities	−2	−6	−8
Accrued interest	0	0	22
Income tax payable	85	−10	10
Other liabilities	−1	773,000	−2
Net cash used in operating activities	−750	−839	−765
Cash flows from investing activities:	—	—	—
Marketable securities, available-for-sale	—	—	—
Purchases	4,796	0	0
Proceeds from maturities	1,122	0	0
Proceeds from sales	821	0	0
Marketable securities, held-to-maturity	—	—	—
Purchases	0	4,062	0
Proceeds from maturities	2,185	1,960	0
Proceeds from sale of Telavant net assets, net	0	110	5,233
Proceeds from sale of subsidiary interests	0	261	48
Cash decrease upon deconsolidation of subsidiaries	4	31	84
Purchase of property and equipment	8	5	1
Other	3	−79,000	−9
Net cash (used in) provided by investing activities	−682	−1,766	5,204
Cash flows from financing activities:	—	—	—
Repurchase of the Company’s common shares	320	1,293	0
Proceeds from issuance of the Company’s common shares, net of issuance costs paid	0	0	200
Proceeds from issuance of subsidiary common shares, net of issuance costs paid	194	113	239
Repayment of debt by subsidiary	0	52	29
Contribution from minority interest holder to subsidiary	39	0	0
Proceeds from exercise of the Company’s and subsidiary stock options	268	50	54
Taxes paid related to net settlement of equity awards	49	37	38
Proceeds from issuance of the Company’s common shares under employee stock purchase plan	1	1	951,000
Payments on principal portion of finance lease obligations	0	774,000	2
Payment of subsidiary dividend	0	0	6
Proceeds from exercise of the Company’s warrants	0	0	5,000
Payment for redemptions of the Company’s warrants	0	0	41,000
Net cash provided by (used in) financing activities	134	−1,220	419
Effect of exchange rate changes on cash, cash equivalents and restricted cash	4	747,000	616,000
Net change in cash, cash equivalents and restricted cash	−1,295	−3,825	4,858
Cash, cash equivalents and restricted cash at end of period	—	—	—
Cash, cash equivalents and restricted cash at end of period	—	—	—
Non-cash investing and financing activities:	—	—	—
Cashless exercise of the Company’s warrants	0	0	−83
Issuance of subsidiary shares in connection with debt renegotiation	0	12	0
Operating lease right-of-use assets obtained and exchanged for operating lease liabilities	−10	−51	−2
Reclassification of earn-out shares liability to additional paid-in capital upon vesting	58	0	0
Taxes payable related to net settlement of equity awards	31	0	0
Other	−3	−59,000	−441,000
Supplemental disclosure of cash paid:	—	—	—
Interest paid	0	6	10

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro